The seroprevalence of hepatitis A and B in people testing positive for hepatitis C [9]

CMAJ. Canadian Medical Association Journal

Volumn 162, Issue 2, 2000, Pages 207-208

  Kiefer, Lori A ^a   Honish, Agnes ^a   Predy, Gerry ^a   Talbot, James A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY TITER; HEPATITIS A; HEPATITIS B; LABORATORY TEST; LETTER; SEROLOGY; SEROPREVALENCE; VIRUS INFECTION;

EID: 0034711771     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (8)

1. Lemon S, Brown E. Hepatitis C virus. In: Mandell G, Bennett J, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone; 1995. p. 1474-85.
2. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-90.
3. World Health Organization. Public health control of hepatitis A: memorandum from a WHO meeting. Bull World Health Organ 1995;73:15-20.
4. National Advisory Committee on Immunization. Hepatitis A vaccine. In: Canadian immunization guide. 5th ed. Ottawa: Health Protection Branch, Laboratory Centre for Disease Control, Health Canada; 1998. p. 83-9.
5. US Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996;45(RR-15):1-30.
6. National Institutes of Health. Management of hepatitis C. National Institutes of Health consensus development conference statement 105 (1997 Mar 24-26). Available: http://text.nlm.nih.gov/nih/cdc/www/105.html (accessed 1999 Dec 23).
7. Préfontaine R, Chaudhary R, Mathias R. Analysis of risk factors associated with hepatitis B and C infection in correctional institutions in British Columbia. Can J Infect Dis 1994;5(4):153-6.
8. Tennant F, Moll D. Seroprevalence of hepatitis A, B, C, and D markers and liver function abnormalities in intravenous heroin addicts. J Addict Dis 1995;14(3):35-49.